Literature DB >> 2591176

In vitro activity of sulbactam in combination with various beta-lactam antibiotics.

J Klastersky1, P Van der Auwera.   

Abstract

Forty-three strains (beta-lactamase positive and negative) from the species of Haemophilus influenzae, Neisseria gonorrhoeae, Staphylococcus aureus, Escherichia coli, Serratia marcescens, Enterobacter cloacae, Acinetobacter baumanii, and Pseudomonas aeruginosa were studied for synergy between sulbactam and several beta-lactam antibiotics. Using a checkerboard method, synergy was observed with 10 to 55% of the beta-lactamase negative strains. Synergy was more frequent with the strains producing beta-lactamase. Using the killing curve method, synergy was also observed between sulbactam and beta-lactam antibiotics against some beta-lactamase negative strains. In addition, the regrowth of a resistant subpopulation was prevented by sulbactam.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2591176     DOI： 10.1016/0732-8893(89)90130-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  7 in total

1.  Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.

Authors:  M Pfaller; A Barry; P Fuchs; E Gerlach; D Hardy; J McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-03       Impact factor: 3.267

2.  In-vitro susceptibility of cefoperazone-susceptible and -resistant gram-negative rods to cefoperazone plus sulbactam, other beta-lactams, aminoglycosides and quinolone.

Authors:  P H Chandrasekar; J A Sluchak
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

3.  Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

4.  Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.

Authors:  P Van der Auwera; V Duchateau; C Lambert; M Husson; M Kinzig; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

5.  Therapy with cefoperazone plus sulbactam against disseminated infection due to cefoperazone-resistant Pseudomonas aeruginosa and Escherichia coli in granulocytopenic mice.

Authors:  P H Chandrasekar; J A Sluchak; J A Kruse
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

6.  Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

7.  Antimicrobial prophylaxis for major head and neck surgery in cancer patients: sulbactam-ampicillin versus clindamycin-amikacin.

Authors:  M Phan; P Van der Auwera; G Andry; M Aoun; G Chantrain; R Deraemaecker; P Dor; D Daneau; P Ewalenko; F Meunier
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.